TOKYO, Oct. 8, 2024 /PRNewswire/ -- Ciconia Bioventures Inc. (Representative Director, Founder CEO: Toshio Fujimoto, "Ciconia") today announced its establishment as a joint venture company based on a ...
AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.
Outsourcing is driving biopharma efficiency and scale, including in the drug discovery area and early phase development.
Researchers from The Ohio State University and the Indian Institute of Technology Madras have developed an artificial intelligence framework to rapidly generate drug-like molecules that are easier to ...
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
Discover how Optibrium is transforming early-stage drug discovery through AI-powered software, generative chemistry, and 3D modelling. In this interview, Matt Segall, CEO at Optibrium, shares insights ...
Predictive Oncology aims to enhance drug discovery using its biobank and AI, following industry trends exemplified by Regeneron's 23andMe acquisition. Predictive Oncology Inc. is leveraging its ...
Recursion Pharmaceuticals RXRX is redefining the traditional model of drug discovery by harnessing the power of artificial intelligence (AI) through its proprietary RecursionOS platform, developed in ...
This episode of the Pharmaron DMPK Insights Podcast Series sees Simon Taylor (Vice President of Drug Discovery at Pharmaron) and Dr. Emile Chen (former Director of Modeling and Translational Biology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results